Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1Breast Neoplasms 1

Interventions

pembrolizumab 25Cisplatin 17Carboplatin 13Radiotherapy 12Cetuximab 9Blood Specimen Collection 9Docetaxel 8Paclitaxel 7Fluorouracil 7Drug Therapy 7toripalimab 6tislelizumab 4nimotuzumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Chemoradiotherapy 4fludarabine 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy, Intensity-Modulated 3Cyclophosphamide 3Biopsy 3130-nm albumin-bound paclitaxel 3cemiplimab 2avelumab 2X-Rays 2Tocopherols 2Tiragolumab 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Head and Neck Neoplasms × Interleukin-15 × Clear all
NCT06239220 2026-02-27

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
25 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡